Back

The German lipoprotein apheresis registry - summary of the thirteenth annual report

30 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Secondary prevention (2) Secondary Prevention ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Anja Vogt

Ludwig Maximilians University, Munich (Germany)

7 More presentations in this session

Presentation thumbnail
The influence of medication costs on secondary cardiovascular prevention decisions: two discrete choice experiments among patients and prescribers
Miss E. Wempe (NL)
Abstract Slides
Presentation thumbnail
Low molecular weight heparin for AMI with frailty: short-Term outcomes after early PCI
Professor K. Chen (Tianjin, CN)
Abstract Slides
Presentation thumbnail
COVID-19 vaccination confers long-term cardioprotection against post-COVID cardiovascular disease: >5-year evidence from causal mediation and target trial emulation
Mr B. Seboka (Melbourne, AU)
Abstract Slides
Presentation thumbnail
The newest pillar is the most fragile: SGLT2 inhibitors show the lowest 12-month ongoing use among guideline-directed CAD medications in a 15-country European survey
Mr L. Kieviet (Utrecht, NL)
Abstract Slides
Presentation thumbnail
Prevalence and characteristics of low-dose acetylsalicylic acid intake in the German population: insights from the German National Cohort (NAKO)
Professor J. Neumann (Hamburg, DE)
Abstract Slides

Access the full session

Session thumbnail
Secondary prevention (2)

The Event

Event poster

ESC Congress 2026

30 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study
27 August 2021
thumbnail
Congress Presentation
Variability of lipoprotein(a) levels in patients hospitalized in an emergency setting
24 April 2026
thumbnail
Congress Presentation
Pelacarsen reduces the need for lipoprotein apheresis in patients with elevated lipoprotein(a) and cardiovascular disease: The Phase 3 Lp(a)FRONTIERS APHERESIS trial
29 August 2025
thumbnail
Congress Presentation
Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources